Included in the formulation
АТХ:V.09.I.B Compounds of indium-111
Pharmacodynamics:Synthetic octapeptide, a somatostatin analogue, superior to it in duration of action. It binds to somatostatin receptors, the density of which is increased on the cells of a number of tumors and their metastases. Does not have pharmacological effects of somatostatin.
Pharmacokinetics:After intravenous administration of 2/3 of the drug leaves the bloodstream after 10 minutes.
The half-life is 6 hours. Elimination of the kidneys unchanged.
Indications:It is used for radionuclide diagnostics of tumors of central nervous system, neuroendocrine tumors, breast cancer, small cell lung cancer.
XXI.Z00-Z13.Z03 Medical surveillance and evaluation in case of suspected disease or pathological condition
II.C999.C999 * Diagnosis of malignant neoplasms
Contraindications:Individual intolerance.
Pregnancy and lactation:Recommendations for FDA - Category C. It is used with caution during pregnancy in cases where the intended benefit exceeds the risk to the fetus. During lactation it is recommended to stop breastfeeding 48 hours before using the drug.
Dosing and Administration:Intravenous bolus, at a dose of 111 MBq for planar scintigraphy and 222 MBq for single-photon emission computed tomography.
The highest daily dose: 222 MBq.
The highest single dose: 222 MBq.
Side effects:Allergic reactions.
Overdose:Cases of overdose are not described.
Treatment is symptomatic.
Interaction:It is not recommended simultaneous application of the drug with other synthetic analogues of somatostatin.
Special instructions:The use of the drug is possible only in a specialized hospital.